ESR1 and breast neoplasm: In fact, anecdotal evidence from daily pathology practice suggests that the concern over missed treatment opportunities prompts many pathologists to categorize breast tumors as ER-positive, even when staining of nuclei does not formally meet the 1% criterion, despite the fact that low ER and/or PR expression has repeatedly been linked to non-luminal biology and endocrine resistance [30–34].